Skip to content
Mesothelioma.net
phone iconCall1-800-692-8608 chat icon Chat 24/7 Live Chat
Menu
  • Malignant Mesothelioma
    • About Mesothelioma
      • How to Survive Mesothelioma
      • 100 Questions & Answers about Mesothelioma (Free Book)
      • Symptoms
      • Diagnosis
      • Prognosis
      • Life Expectancy
    • Types
      • Pleural
      • Peritoneal
      • Epithelioid
      • Sarcomatoid
      • Biphasic
    • Stages
      • Stage 1
      • Stage 2
      • Stage 3
      • Stage 4
    • Additional Information
      • Causes
      • Asbestos and Its Dangers
      • Facts
      • Support
      • Financial Compensation
      • FREE Mesothelioma Packet
  • Treatment
    • Treatment Options
      • Surgery
      • Chemotherapy
      • Radiation Therapy
      • Multimodal Therapy
      • Medications
      • Palliative Treatment
    • Find Top Doctors
      • Doctors
      • Treatment Centers
      • Treatment & Doctors Near You
      • New Treatments
      • Care Providers
      • Clinical Trials
      • Costs
  • Asbestos Trusts
  • Compensation
  • Veteran Assistance
    • Mesothelioma and Veterans
      • VA Claims for Mesothelioma
      • Vietnam Veterans
    • Military Branches and Asbestos
      • Navy Veterans
      • Navy Ships
      • Marine Corps Veterans
      • Army Veterans
      • Air Force Veterans
      • U.S. Coast Guard
  • Surviving Mesothelioma
  • About Us / Contact
  • Home
  • ›
  • Malignant Mesothelioma
  • ›
  • Treatment
  • ›
  • Medications
  • ›
  • Sutent (sunitinib)
Page Updated: July 01, 2022

Sutent (sunitinib)

Kyle J. Becker Page Medically Reviewed and Edited by Kyle J. Becker, PharmD, MBA, BCOP

FREE Mesothelioma Packet

Fact Checked

This page has been fact checked by a Doctor of Pharmacy who specializes in Oncology. Sources of information are listed at the bottom of the article.

FREE Mesothelioma Packet

We make every attempt to keep our information accurate and up-to-date.

Please Contact Us with any questions or comments.

Sutent (sunitinib) is an oral medication approved to treat carcinoid tumors and kidney cancer different from standard chemotherapy. Recent studies show this drug could help some patients with mesothelioma. Continued research is needed to discover biomarkers that could determine which patients would benefit from Sutent.

FREE Mesothelioma Packet

What Is Sutent?

Sutent is the brand name of a medication with the generic name of sunitinib. It was first approved by the FDA in 2006 and is used to treat advanced renal cell cancer, pancreatic neuroendocrine tumors in patients who are not candidates for surgery, and gastrointestinal stromal tumors that do not respond well to other treatments.

Unlike many chemotherapy drugs, Sutent is taken as an oral tablet, making dosing more convenient for patients. Like traditional chemotherapy, Sutent is given in cycles. There is time allotted between cycles for the body to recover from treatment. Although Sutent is not approved for mesothelioma, studies are underway to determine if it could be used as an effective treatment.[1]

How it Works

Sutent is a multi-receptor tyrosine kinase inhibitor. It targets several cell receptors and kinases, enzymes on the surface of cells. These enzymes play an important role in how cancer grows and spreads. By targeting these enzymes, Sutent halts signaling inside the cell. Specifically, it inhibits the formation of new blood vessels required for tumor growth. It also inhibits the division of cancer cells and helps trigger cell death.

Some types of cancers are especially driven by mutations in receptor tyrosine kinases. This is why Sutent was first approved for a few particular cancers. This is also the reason Sutent may work for some mesothelioma patients. Mesothelioma is a complex cancer and is different in every individual.

In some patients, the receptor tyrosine kinases play an important role in how the cancer grows, while in other patients, they may not. Researchers are still investigating which patients can benefit from this targeted drug therapy.

Side Effects

Even with highly targeted drugs, there are potential side effects and adverse reactions. For Sutent, the most commonly reported side effects are:[1]

  • Fatigue
  • Weakness
  • Fever
  • Nausea
  • Diarrhea
  • Vomiting
  • High blood pressure
  • Abdominal pain
  • Peripheral edema
  • Constipation
  • Skin rashes
  • Skin discoloration
  • Skin dryness
  • Back pain
  • Changes in taste
  • Cough
  • Shortness of breath
  • Anorexia
  • Bleeding

Sutent can also cause hand and foot syndrome, resulting in cracked skin, stinging sensation, redness, swelling, thickening, and blistering on the palms of the hands and soles of the feet.

Black Box Warnings

The FDA reserves the black box warning for serious side effects and complications that may be severe or life-threatening. Sutent carries a black box warning concerning liver toxicity.

The drug has been shown to sometimes cause significant damage to the liver. This damage could be potentially severe and life-threatening. Patients should be carefully screened for liver damage before using Sutent and continue regular liver monitoring while taking it.

Some patients with a history of liver disease or heavy alcohol use may not be good candidates for the drug. Patients should watch for signs of liver damage, including yellowing eyes and skin, itchiness, dark urine, and pain in the upper right abdominal area.[1]

Sutent and Mesothelioma

Sutent is not approved by the FDA to treat mesothelioma; however, researchers are evaluating it as a possible treatment for this difficult cancer.

Because Sutent is a targeted drug and the molecular makeup of cancer differs between each patient, some patients may respond well while others do not; therefore, this drug will affect tumor growth in some patients and not others. This is in contrast to traditional chemotherapy drugs, which are not very targeted and tend to work on any fast-growing cells, cancerous or healthy.

Preliminary results from a phase II clinical trial with Sutent show that this drug may not be useful in mesothelioma patients as a single agent. Overall average survival time was just over eight months, which is not a great improvement over other treatments.[2]

However, other studies have been more promising. One phase II clinical trial involving fifty-three mesothelioma patients who had previously undergone chemotherapy that did not slow disease progression showed some positive effects.

In this study, 12% of patients had a reduction in tumor size, and 65% saw stable disease. Only 22% of the patients saw no benefit. Researchers attempted to determine if certain biomarkers could indicate which patients would respond well to Sutent but were unsuccessful.

They concluded that the drug should be used in mesothelioma patients. However, more work is necessary to pinpoint biomarkers to help determine which patients will respond favorably to the drug.[3]

Sutent is a new targeted therapy that can potentially treat various types of cancer, possibly including mesothelioma. Targeted drugs like Sutent make cancer treatment more individualized and hopefully more effective with fewer patients not responding to treatment.

Currently, Sutent may have some value in treating mesothelioma, but not in all patients. As researchers discover more about the medication and disease, they hope to identify biomarkers that will indicate who will benefit from treatment with Sutent.

Get Your FREE Mesothelioma Packet

Page Medically Reviewed and Edited by Kyle J. Becker, PharmD, MBA, BCOP

Kyle J. Becker

Kyle J. Becker, PharmD is certified by the Board of Pharmacy Specialties in Oncology Pharmacy. Dr. Becker earned his pharmacy degree from Shenandoah University and he currently serves as an oncology pharmacist at Parkview Cancer Institute.

Connect with Oncology Pharmacist Kyle J. Becker
References
  1. MedlinePlus. (2018, January 15). Sunitinib.
    Retrieved from: https://medlineplus.gov/druginfo/meds/a607052.html
  2. Laurie, S.A., Gupta, A., Chu, Q., Lee, C.W., Morzycki, W., Feld, R., Foo, A.H., Seely, J., Goffin, J.R., Laberge, F., Murray, N., Rao, S., Nicholas, G., Laskin, J., Reiman, T., Sauciuc, D., and Seymour, L. (2011, November). Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group. J. Thorac. Oncol. 6(11), 1950-4.
    Retrieved from: https://www.ncbi.nlm.nih.gov/pubmed/22005473
  3. Nowak, A.K., Millward, M.J., Creaney, J., Francis, R.J., Dick, I.M., Hasani, A., van der Schaaf, A., Segal, A., and Musk, A.W. (2012). A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma. J. Thorac. Oncol. 7, 1449-56.
    Retrieved from: https://www.jto.org/article/S1556-0864(15)32946-4/pdf
View All References

Site Navigation

Home
Malignant Mesothelioma
How to Survive Mesothelioma
100 Questions & Answers about Mesothelioma (Free Book)
Surviving Mesothelioma - Beating the Odds (Free Book)
FREE Mesothelioma Packet
Symptoms
Shortness of Breath
Cough
Night Sweats and Fever
Weight Loss
Pain
Difficulty Swallowing
Fatigue and Muscle Weakness
Gastrointestinal Complications
Diagnosis
Pathology
Staging
Stage 1
Stage 2
Stage 3
Stage 4
Metastasis and Progression
Brain Metastasis
Biopsy
miRview Test
Imaging
Fine Needle Aspiration Biopsy in Mesothelioma
Biomarkers and Blood Tests
Calretinin
Prognosis
Remission
Recurrence
Death Rate
Life Expectancy
Search for a Mesothelioma Cure
Types
Pleural
Peritoneal
Epithelioid
Sarcomatoid
Biphasic
Pericardial
Testicular
Cell Types
Rare Subtypes of Mesothelioma
Deciduoid
Desmoplastic
Heterologous
Lymphohistiocytoid
Well-Differentiated Papillary
Tubulopapillary
Small Cell
Benign
Adenomatoid
Cystic
Unresectable
Localized
Idiopathic
Omental
Causes
Risk Factors
Latest Research
Genetic Components
Incidence
Latency Period
Mesothelioma Tumor
Health Insurance Coverage
Related Conditions
Immunodeficiency Disorders
Cholangiocarcinoma
Atelectasis
Pleural Plaques
Pleural Thickening
Pleural Effusion
Peritoneal Effusion (Ascites)
Mesothelial Hyperplasia and Proliferation
Pleuritis and Pleurisy
COPD
Anemia
Breast Cancer
Prevention
Complications
Misdiagnosis
Mesothelioma Commercial
Talcum Baby Powder
Lawyer
Lawsuits
Class Action Lawsuits
Settlements
Simian Virus 40
Differences From Other Cancers
Lung Cancer
Women
Children and Young Adults
Unknown Asbestos Exposure
Mesothelioma Without Asbestos
Cause of Death
Facts 
History
Awareness
Government and Research
National Mesothelioma Virtual Bank
Support
What to Expect
Living with Mesothelioma
Help a Loved One
Wrong and Right Things to Say
Caregivers
Financial Tips
Faith
Nutrition and Lifestyle
Intimacy
Mesothelioma and Fertility in Men
Fertility in Women with Mesothelioma
Emotional Health
COVID-19
Assisted Living
Hospice Care
Dying from Mesothelioma
Mourning
Coping Guide for Children
End-of-Life Decisions
Mesothelioma Awareness Day
Compensation for Victims
Lawyer
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington D.C.
Washington
West Virginia
Wisconsin
Wyoming
Lawsuit
Settlements
Statute of Limitations
Treatment
Surgery
Side Effects
Pneumonectomy
Extrapleural Pneumonectomy
Lobectomy
Pleurectomy/Decortication
Post Op Care
Pleurectomy/Decortication vs. Extrapleural Pneumonectomy
Peritonectomy/Cytoreductive Surgery
Thoracotomy
Thoracoscopy
Pericardiectomy
Wedge Resection
Pleurodesis
Pericardiocentesis
Prosthetics
Paracentesis
Thoracentesis
Chemotherapy
Side Effects
Heated Intraperitoneal
Radiation Therapy
Side Effects
Intensity-Modulated
Brachytherapy
Proton Therapy
Image-Guided
External Beam
Three-Dimensional
Multimodal Therapy
New Treatments
SMART Protocol
Gene Therapy
Suicide Gene Therapy
Tumor-Based p53 Therapy
Cryotherapy for Mesothelioma
Tumor Treating Fields
MicroRNA
Palliative Treatment
Osteopathic
Doctors
Treatment Centers
Treatment & Doctors Near You
Mesothelioma Experts
Medications
Alimta (pemetrexed)
Adriamycin (doxorubicin)
Avastin (bevacizumab)
Cytoxan (cyclophosphamide)
Gemzar (gemcitabine)
Keytruda (Pembrolizumab)
Mitomycin
Navelbine (vinorelbine)
Opdivo (nivolumab) and Yervoy (ipilimumab)
Paraplatin (carboplatin)
Platinol (cisplatin)
Rheumatrex (methotrexate)
Sutent (sunitinib)
Taxol (paclitaxel)
Medical Marijuana
Care Providers
Clinical Trials
Anetumab Ravtansine
Atezolizumab
Chimeric Antigen Receptor (CAR) T-Cell
Durvalumab
Immunotoxin
Interferon Alfa-2b
Onconase (Ranpirnase)
VISTA Protein
Costs
Immunotherapy
Nanotechnology
Hyperbaric Oxygen Therapy
Home Medical Equipment
HMGB1 Secretion
Photodynamic Therapy
Targeted Therapies
Apoptosis
Stem Cells
Lung Transplantation
Body-Based Therapies
Alternative Therapies
Paul Kraus’s Method
Doctors and Treatment in Canada
Asbestos Trusts
Veterans
VA Claims for Mesothelioma
Vietnam Veterans
Military Branches and Asbestos
Navy Veterans
Navy Ships
Aircraft Carriers
Battleships
Destroyers
Asbestos on Navy Cruisers
Submarines
Amphibious Ships
Minesweepers
Auxiliary Ships
Marine Corps Veterans
Army Veterans
Air Force Veterans
U.S. Coast Guard
Asbestos
Occupational Exposure
Construction Workers
Shipyard Workers
Ship Repair
Steel Mill Workers
Industrial Workers
Boiler Workers
Power Plant Workers
Firefighters
Automotive Workers
Roofers
Oil Refineries
Mining
Transportation Industry
Machine Operators
Farmers and Agricultural Workers
Migrant Workers
Electrical Wiring
Labor Unions
Prisons
Chimneys, Furnaces, and Wood Stoves
Fiberglass Connection to Mesothelioma
Home Remodeling
School Buildings, Teachers
For Tech Students
Cancer
Lung Cancer
Pleural Based Cancers
Ovarian Cancer
Ovarian Cancer Lawsuits
Companies That Used Asbestos
Awareness and Education
Types of Asbestos & Mesothelioma Risk
Asbestosis
Interstitial Lung Disease
Smoking
Asbestos Ingestion
Exposure in a Natural Disaster
Ban Asbestos
Libby, Montana
Recycling Asbestos
Asbestos Detection
Legal Information by State
Canada
Mexico
United Kingdom
Australia
  • Malignant Mesothelioma
    • Treatment
    • Asbestos Trusts
  • Compensation
    • Veteran Assistance
    • Surviving Mesothelioma
  • FREE Mesothelioma Packet
    • Mesothelioma News
    • About Us / Contact
  • Privacy Policy
    • Disclaimer
    • Editorial Guidelines and Standards
This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.
The information provided by Mesothelioma.net is not a substitute for professional medical advice, diagnosis or treatment.

Mesothelioma.net

5430 LBJ Freeway Suite 1200
Dallas, Texas 75240

Serving mesothelioma victims nationwide

1-800-692-8608

  • facebook
  • twitter
© 2022 Mesothelioma.net